Prospective comparison of [
Neuroendocrine tumor
PET
PET/MR
Somatostatin receptor
[18F]AlF-NOTA-octreotide
[68Ga]Ga-DOTATATE
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
received:
06
03
2023
accepted:
22
05
2023
medline:
1
6
2023
pubmed:
1
6
2023
entrez:
1
6
2023
Statut:
epublish
Résumé
Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [ Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [ In total, 195 unique lesions were detected: 167 with [ The DR of [ gov/study/NCT04552847.
Sections du résumé
BACKGROUND
BACKGROUND
Fluorine-18-labeled SSAs have the potential to become the next-generation tracer in SSTR-imaging in neuroendocrine tumor (NET) patients given their logistical advantages over the current gold standard gallium-68-labeled SSAs. In particular, [
METHODS
METHODS
Ten patients with a histologically confirmed neuroendocrine tumor (NET) and a standard-of-care [
RESULTS
RESULTS
In total, 195 unique lesions were detected: 167 with [
CONCLUSION
CONCLUSIONS
The DR of [
CLINICALTRIALS
RESULTS
gov/study/NCT04552847.
Identifiants
pubmed: 37261615
doi: 10.1186/s13550-023-01003-3
pii: 10.1186/s13550-023-01003-3
pmc: PMC10235004
doi:
Banques de données
ClinicalTrials.gov
['NCT04552847']
Types de publication
Journal Article
Langues
eng
Pagination
53Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023. The Author(s).
Références
Mol Imaging Biol. 2017 Oct;19(5):779-786
pubmed: 28280965
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):51-60
pubmed: 31410538
Cancers (Basel). 2020 Jun 08;12(6):
pubmed: 32521645
J Nucl Med. 2023 Feb;64(2):204-210
pubmed: 36725249
Eur J Nucl Med Mol Imaging. 2014 May;41(5):887-97
pubmed: 24352789
Endocrinol Metab Clin North Am. 2018 Sep;47(3):505-523
pubmed: 30098713
Endocrine. 2017 Nov;58(2):368-379
pubmed: 28303513
J Nucl Med. 2022 Oct;63(10):1537-1543
pubmed: 35115367
J Nucl Med. 2020 Dec;61(12):1764
pubmed: 33262268
EJNMMI Res. 2021 Jun 9;11(1):55
pubmed: 34106351
J Nucl Med. 2018 Jan;59(1):66-74
pubmed: 29025982
EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4
pubmed: 31997090
Abdom Imaging. 2015 Aug;40(6):1432-40
pubmed: 25820755
Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):311-331
pubmed: 30510849
J Neuroendocrinol. 2021 May 14;33(6):e12981
pubmed: 34046974
Cancers (Basel). 2021 Dec 28;14(1):
pubmed: 35008293
Eur Radiol. 2014 Apr;24(4):889-901
pubmed: 24322510
Int J Cancer. 2016 Dec 15;139(12):2679-2686
pubmed: 27553864
Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046
pubmed: 32617641
Neuroendocrinology. 2017;104(3):264-272
pubmed: 27120316
J Nucl Med. 2010 Mar;51(3):454-61
pubmed: 20150268
J Nucl Med. 2023 Apr;64(4):632-638
pubmed: 36265911
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1588-1601
pubmed: 28547177
J Nucl Med. 2017 Mar;58(3):451-457
pubmed: 27660147
J Nucl Med. 2016 Dec;57(12):1949-1956
pubmed: 27811124
J Nucl Med. 2014 Oct;55(10):1598-604
pubmed: 25168627
Cancer Imaging. 2013 Mar 05;13:63-72
pubmed: 23466785
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Abdom Radiol (NY). 2022 Feb;47(2):586-595
pubmed: 34757459
Abdom Radiol (NY). 2022 Dec;47(12):4058-4072
pubmed: 35426497
Radiographics. 2015 Mar-Apr;35(2):500-16
pubmed: 25763733